Purpose: To prospectively estimate measurement and scan reproducibility of parameters of intravoxel incoherent motion (IVIM) in renal tumors, normal renal cortex, and medulla.
Methods: Twenty-four consecutive patients (twelve males and twelve females; median age 56.7 years, range 32-71 years) with 25 renal tumors (20 renal cell carcinomas, one urothelium carcinoma, three angiomyolipomas, and one oncocytoma) were examined twice using IVIM and IVIM with 9 and 16 b values, respectively, at 3.0 T. All the patients were re-scanned in 24-48 h. Regions of interest (ROIs) were placed in solid part of tumor, normal cortex, and medulla to derive IVIM parameters D (true diffusion coefficient), D* (pseudodiffusion coefficient), and f (perfusion fraction of pseudodiffusion). Differences in parameters between two IVIM sets and intra-observer, inter-observer, and scan-rescan differences were assessed using paired t tests. Intra-observer, inter-observer, and scan-rescan reproducibility were assessed by measuring coefficient of variation and Bland-Altman limits of agreements.
Results: Intra-observer reproducibility of renal tumors, normal renal cortex, and medulla was excellent for apparent diffusion coefficient (ADC; CV: 3.45%-5.34%, BA-LA: -14% to 18%) and D (CV: 3.65% to 6.04%, BA-LA: -18% to 19%), good for f (CV: 11.96%-16.08%, BA-LA: -76.4% to 92.1% except f of medulla with CV of 32.59% and BA-LA of -76.4% to 92.1% in IVIM), and poor for D* (CV: 25.0% to 75.4%, BA-LA: -111% to 150%). The same order was in inter-observer reproducibility analysis. Scan-rescan reproducibility was the worst of the three parameters. Renal medulla showed worse reproducibility than renal tumors and the normal cortex. The metrics of IVIM had better reproducibility than IVIM.
Conclusion: Excellent reproducibility evaluation for ADC and D, good for f, and poor for D* derived from IVIM was performed in renal tumors, normal renal cortex, and medulla. D* has limited reliability and scan-rescan reproducibility should be improved.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00261-017-1361-7 | DOI Listing |
PLoS One
January 2025
Cardiovascular Outcomes Research Laboratories (CORELAB), University of California, Los Angeles, Los Angeles, CA, United States of America.
Purpose: Patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) have been noted to face increased cancer incidence. Yet, the impact of concomitant renal dysfunction on acute outcomes following elective surgery for cancer remains to be elucidated.
Methods: All adult hospitalizations entailing elective resection for lung, esophageal, gastric, pancreatic, hepatic, or colon cancer were identified in the 2016-2020 National Inpatient Sample.
IUBMB Life
January 2025
Department of Pathology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong Institute of Nephrology, Jinan, China.
Clear cell renal cell carcinoma (KIRC) is the most prevalent subtype of renal cell carcinoma (RCC), accounting for 70% to 80% of all RCC cases. The CRYAB (αB-crystallin) gene is broadly expressed across various human tissues, yet its role in KIRC progression remains unclear. This study aims to elucidate the function of CRYAB in KIRC progression and to assess its potential as a biomarker for early diagnosis, therapeutic targeting, and prognosis.
View Article and Find Full Text PDFToxins (Basel)
January 2025
Graduate School of Natural Science and Technology, Shimane University, 1060 Nishikawatsu-cho, Matsue 690-8504, Shimane, Japan.
Epidemiological studies suggest an increased risk of colorectal cancer (CRC) aggravation in patients with chronic kidney disease (CKD). Our previous study demonstrated that indoxyl sulfate, a uremic toxin whose concentration increases with CKD progression, exacerbates CRC through activation of the AhR and Akt pathways. Consequently, indoxyl sulfate has been proposed to be a significant link between CKD progression and CRC aggravation.
View Article and Find Full Text PDFToxins (Basel)
December 2024
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Despite the popular belief in the anti-tumor properties of venom (VBV), there is limited scientific evidence to support this claim. This study is the first to examine the anti-tumor effects of VBV on liver cancer, both alone and in combination with cisplatin (DDP), through in vitro and in vivo experiments. In vitro experiments evaluated VBV and its combination with DDP on HepG2 cell proliferation, invasion, migration, and apoptosis.
View Article and Find Full Text PDFTomography
January 2025
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Objectives: Accurate kidney and tumor segmentation of computed tomography (CT) scans is vital for diagnosis and treatment, but manual methods are time-consuming and inconsistent, highlighting the value of AI automation. This study develops a fully automated AI model using vision transformers (ViTs) and convolutional neural networks (CNNs) to detect and segment kidneys and kidney tumors in Contrast-Enhanced (CECT) scans, with a focus on improving sensitivity for small, indistinct tumors.
Methods: The segmentation framework employs a ViT-based model for the kidney organ, followed by a 3D UNet model with enhanced connections and attention mechanisms for tumor detection and segmentation.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!